Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The Senate HELP Committee has scheduled a confirmation hearing for Dr. Heidi Overton, Trump's pick to lead the FDA, on September 24. Overton, a preventive medicine physician and White House policy aide, would inherit an agency that has lost over 3,000 staff and is mired in controversy over vaccines, the abortion pill, and drug approvals. Her nomination signals a continued "America First" approach to federal health leadership.
The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee has set a September 24 confirmation hearing for Dr. Heidi Overton, President Trump's nominee to lead the Food and Drug Administration. Overton, a preventive medicine physician who currently serves as deputy director of the White House Domestic Policy Council, was nominated in August after previously working at the conservative America First Policy Institute.
If confirmed, Overton will step into a deeply turbulent agency. Her predecessor, Marty Makary, resigned in May after just 13 months following clashes with White House officials over flavored vapes, a stalled abortion-pill safety study, and public disputes with drugmakers over reviews of potentially lifesaving medicines and vaccines. The FDA is also grappling with a significant leadership vacuum and a battered public image.
By the Numbers:
Why it matters: The FDA oversees the approval of all drugs, treatments, and vaccines in the U.S., making stable and credible leadership critical for public health and industry confidence. Overton's confirmation—and the policy direction she brings—could shape vaccine schedules, drug approvals, and the agency's independence for years to come.
